Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 123

Sort by

Sort Order Select

Journal Articles

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Blood (2024) 144 (Supplement 1): 7221.

https://doi.org/10.1182/blood-2024-201063

Published: 2024

Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Blood (2024) 144 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2024-206608

Published: 2024

Journal Articles

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Blood (2024) 144 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2024-203871

Published: 2024

Journal Articles

Title: Development of a Pathologic Prognostic Index (PPI) for Newly Diagnosed Large B Cell Lymphoma Patients Treated with R-CHOP

Vincent Ni, Sunita D. Nasta, Stefan K. Barta, Stephen J. Schuster, Elise A. Chong, Jakub Svoboda, Jennifer JD Morrissette, Ashley Barlev, Adam Bagg, Salvatore F. Priore, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 3083.

https://doi.org/10.1182/blood-2024-203448

Published: 2024

Journal Articles

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Benjamin F. Frost, Noelle Frey, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W Loren, Jakub Svoboda, Daniel J. Landsburg, Bruce Levine, Joseph A. Fraietta, J. Joseph Melenhorst, Elizabeth Veloso, Wei-Ting Hwang, Carl H. June, David L. Porter, Saar Gill

Blood (2024) 144 (Supplement 1): 588.

https://doi.org/10.1182/blood-2024-204197

Published: 2024

Journal Articles

Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2 nd Line CAR T Therapy

Michael Schneider, Elise A. Chong, Stefan K. Barta, Sunita D. Nasta, Jakub Svoboda, Jordan Carter, Michael Roderick Cook, Nasheed Hossain, Stephen J. Schuster, Heather Difilippo, John P Plastaras, Michael Lariviere, Marco Ruella, David L. Porter, Noelle Frey, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 5123.

https://doi.org/10.1182/blood-2024-202736

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Richard T. Maziarz, Amy Moskop, Leslie L. Popplewell, Scott R. Solomon, Michael T. Tees, Yongzi Yu, Aiesha Zia, Stephen Lim, Avishek Pal, Pei Hsu, Frederick Locke

Blood (2024) 144 (Supplement 1): 4398.

https://doi.org/10.1182/blood-2024-204207

Published: 2024

Journal Articles

Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania

Nikita Dave, Veronica Carvajal, Jordan Carter, Donald Edward Tsai, Stephen J. Schuster, James Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Daniel J. Landsburg, Sunita D. Nasta

Blood (2024) 144 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2024-207781

Published: 2024

Journal Articles

Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone

Alison Carulli, Hayden Elliott, Brendan Mangan, James Whittenburg, Elise A. Chong, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, David L. Porter, Jordan S. Carter, Michael Roderick Cook, Nasheed Hossain, Saar Gill, Alfred L. Garfall, Christopher Catania, Colleen R. Kucharczuk, Stephen J. Schuster, Noelle Frey, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2024-203726

Published: 2024

Journal Articles

Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5 th Edition of the Who Classification

Guido Ghilardi, Emeline R. Chong, Luca Paruzzo, Giulia Gabrielli, Sunita D. Nasta, Vrutti Patel, Eugenio Fardella, Daniel J. Landsburg, Jordan Carter, Colin Thomas, Stefan K. Barta, Elise A. Chong, Jakub Svoboda, Marco Ruella, Stephen J. Schuster

Blood (2024) 144 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2024-206027

Published: 2024

Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2024-198153

Published: 2024

Journal Articles

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

Reid M. Muenzen, Emeline R. Chong, Dylan Therwhanger, Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, Mitchell E. Hughes, Elizabeth Weber, Marco Ruella, Noelle V. Frey, David L. Porter, Stephen J. Schuster, Elise A. Chong

Blood (2023) 142 (Supplement 1): 2341.

https://doi.org/10.1182/blood-2023-190434

Published: 2023

Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault

Blood (2023) 142 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2023-179387

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

TP53 Mutations Detected By Clinical Laboratory Mutation Analysis Predict for Inferior Clinical Outcomes in Patients with Newly-Diagnosed Aggressive B Cell Lymphomas, Including Those with High-Risk Features

Daniel J. Landsburg, Jennifer JD Morrissette, Sunita D. Nasta, Stefan K. Barta, Stephen J Schuster, Jakub Svoboda, Elise A. Chong, Adam Bagg

Blood (2023) 142 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2023-186343

Published: 2023

Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Blood (2023) 142 (Supplement 1): 308.

https://doi.org/10.1182/blood-2023-183001

Published: 2023

Journal Articles

Impact of Psychological Distress on Immune Phenotype in CLL/SLL Patients Managed By Active Observation

Carolyn Y. Fang, Jakub Svoboda, Adam D. Cohen, Henry C. Fung, Richard I. Fisher, Elizabeth Handorf, Hatcher Ballard, Stefan K. Barta, Daniel J. Landsburg, Dwivedy S. Nasta, Stephen J Schuster, Rashmi Khanal, Alexander W. MacFarlane, Kerry S. Campbell

Blood (2023) 142 (Supplement 1): 6526.

https://doi.org/10.1182/blood-2023-189330

Published: 2023

Journal Articles

Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma

Benjamin Frost, Jennifer JD Morrissette, Stephen J Schuster, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, Elise A. Chong, Marco Ruella, Adam Bagg, Daniel J. Landsburg

Blood (2023) 142 (Supplement 1): 3518.

https://doi.org/10.1182/blood-2023-186553

Published: 2023

Journal Articles

CD5 Expression in Mature T Cell Lymphoma

Miao Cao, Montreh Tavakkoli, Elise A. Chong, Jordan S Carter, Marco Ruella, Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Stephen J Schuster, Stefan K. Barta

Blood (2023) 142 (Supplement 1): 6195.

https://doi.org/10.1182/blood-2023-188043

Published: 2023

NARROW

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Title: Development of a Pathologic Prognostic Index (PPI) for Newly Diagnosed Large B Cell Lymphoma Patients Treated with R-CHOP

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2 nd Line CAR T Therapy

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania

Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone

Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5 th Edition of the Who Classification

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

TP53 Mutations Detected By Clinical Laboratory Mutation Analysis Predict for Inferior Clinical Outcomes in Patients with Newly-Diagnosed Aggressive B Cell Lymphomas, Including Those with High-Risk Features

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Impact of Psychological Distress on Immune Phenotype in CLL/SLL Patients Managed By Active Observation

Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma

CD5 Expression in Mature T Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only